Access brought to you by: LOCKSS

Rheumatoid Arthritis Clinical Trials

Study Confirms Biosimilarity of HD203 and Etanercept in Patients with RA
24-Week Data from the Phase 4 ADACTA Trial
12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA
Naïve to Biologic Therapy or Inadequate Responders to TNF-α Inhibitors: A Phase 2 Study of LY2439821
LITHE Study Subset: Identification of Tocilizumab Early Response-Associated Biomarkers
Adalimumab Plus Methotrexate versus Methotrexate Monotherapy in Early RA
Clinical and Radiological Outcomes of Four DAS ≤2.4 Targeted Treatment Strategies: Eight-Year Results from the BeSt Study
Reduced CV Risk with Use of MTX and TNF-α Inhibitors in Patients with RA
PRESERVE Trial: Patients with Moderately Active RA Achieve and Maintain Low Disease Activity and Remission with Anti-TNF Therapy More Successfully than Those with High Disease Activity
One-Year Results of the SWEFOT Trial

Pages